Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EPS Corporation
• Treatments: Bevacizumab; Cetuximab; Fluorouracil; Liver Extracts; Oxaliplatin

Criteria

Inclusion Criteria:

• Patients who registered the ATOM trial and signed informed consent prior to initiation of any trial-specific procedure and treatment.

Exclusion Criteria:

• None